SCHEDULE 13G/A: Perceptive Advisors Discloses 3.7% Passive Stake in Ensysce Biosciences
Beneficial Ownership Report
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has filed an amendment to disclose a passive 3.7% beneficial ownership stake in Ensysce Biosciences, Inc.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Ensysce Biosciences, Inc.
- The Reporting Persons collectively beneficially own 86,666 shares of Ensysce Biosciences, Inc. Common Stock.
- This ownership represents 3.7% of the Issuer's Common Stock outstanding, based on 2,370,698 shares outstanding as of April 28, 2025, as reported in the Issuer's Form S-3 registration statement filed on May 2, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds the 86,666 shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors, leading to their deemed beneficial ownership of the same shares.
- The filing indicates that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G Amendment), indicating a passive investment. It does not contain information that would inherently suggest positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an investment firm in a publicly traded company, common in the financial industry for transparency regarding significant holdings.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, albeit passive, institutional ownership stake in the company.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement |
| 04/28/2025 | Date as of which 2,370,698 shares of Common Stock were reported outstanding in the Issuer's Form S-3 |
| 05/02/2025 | Date the Issuer's registration statement on Form S-3 was filed with the SEC |
| 05/15/2025 | Date of filing of this Schedule 13G Amendment No. 3 |
Keywords
Ensysce Biosciences, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.